DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo


company name or ticker

Orexigen: Contrave Sales Pop, Equity Response Muted

Orexigen Has Contrave Recapturing Early-Year Form, But Needs European Launch

Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War

Building a better mousetrap.

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough

What Novo Nordisk's Entry Into The Obesity Space Means To The Sector

Orexigen Faces Generic Challenge For Anti-Obesity Drug

VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

Vivus Sales Remain Flat - Stock Trend Not Good

See More Articles...